Innoviva (INVA) Research & Development (2010 - 2026)
Innoviva posted quarterly Research & Development of $5.2 million for Q1 2026, up 19.22% year-on-year from $4.4 million in Q1 2025, and down 44.24% on a QoQ basis from $9.4 million in Q3 2025.
Innoviva (INVA) has 15 years of Research & Development data on file, last reported at $5.2 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 19.22% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $27.0 million (up 87.83% YoY), and the FY2025 full-year result was $30.6 million, up 124.14% from the prior year.
- Research & Development for Q1 2026 stood at $5.2 million, down from $9.4 million in the prior quarter.
- Across five years, Research & Development topped out at $15.0 million in Q2 2023 and bottomed at $2.6 million in Q2 2024.
- The 5-year median for Research & Development is $5.8 million (2022), against an average of $7.7 million.
- The widest annual swing landed in 2022, when Research & Development surged 36436.84%; it then slumped 82.92% in 2024.
- A 5-year view of Research & Development shows it stood at $11.7 million in 2022, then sank by 65.98% to $4.0 million in 2023, then declined by 10.98% to $3.6 million in 2024, then surged by 164.71% to $9.4 million in 2025, then slumped by 44.24% to $5.2 million in 2026.
- The last three Research & Development figures came in at $5.2 million (Q1 2026), $9.4 million (Q3 2025), and $8.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 5.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.24 Mn |
| Sep 30, 2025 | 9.40 Mn |
| Jun 30, 2025 | 7.98 Mn |
| Mar 31, 2025 | 4.40 Mn |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Mar 31, 2024 | 3.88 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Jun 30, 2023 | 14.99 Mn |
| Mar 31, 2023 | 12.59 Mn |
| Sep 30, 2022 | 11.73 Mn |
| Jun 30, 2022 | 13.88 Mn |
| Mar 31, 2022 | 5.84 Mn |
| Sep 30, 2021 | 449,000.00 |
| Jun 30, 2021 | 38,000.00 |
| Mar 31, 2021 | 49,000.00 |
| Dec 31, 2020 | 219,000.00 |
| Sep 30, 2020 | 1.01 Mn |
| Jun 30, 2020 | 559,000.00 |
| Dec 31, 2017 | 342,000.00 |
| Sep 30, 2017 | 311,000.00 |
| Jun 30, 2017 | 348,000.00 |
| Mar 31, 2017 | 354,000.00 |
| Dec 31, 2016 | 345,000.00 |
| Sep 30, 2016 | 286,000.00 |
| Jun 30, 2016 | 370,000.00 |
| Mar 31, 2016 | 392,000.00 |
| Dec 31, 2015 | 722,000.00 |
| Sep 30, 2015 | 547,000.00 |
| Jun 30, 2015 | 638,000.00 |
| Mar 31, 2015 | 712,000.00 |
| Dec 31, 2014 | 777,000.00 |
| Sep 30, 2014 | 1.91 Mn |
| Jun 30, 2014 | 2.13 Mn |
| Mar 31, 2014 | 2.69 Mn |
| Dec 31, 2013 | 2.48 Mn |
| Sep 30, 2013 | 2.10 Mn |
| Jun 30, 2013 | 2.41 Mn |
| Mar 31, 2013 | 26.42 Mn |
| Dec 31, 2012 | -81.63 Mn |
| Sep 30, 2012 | 27.03 Mn |
| Jun 30, 2012 | 29.55 Mn |
| Mar 31, 2012 | 33.20 Mn |
| Dec 31, 2011 | 32.47 Mn |
| Sep 30, 2011 | 27.84 Mn |
| Jun 30, 2011 | 22.80 Mn |
| Mar 31, 2011 | 20.46 Mn |
| Dec 31, 2010 | 17.48 Mn |
| Sep 30, 2010 | 18.54 Mn |
| Jun 30, 2010 | 18.71 Mn |